Assembly Biosciences Inc (ASMB)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Assembly Biosciences Inc (ASMB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011824
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Assembly Biosciences Inc (Assembly), formerly Ventrus Biosciences Inc is a biotechnology company that discover, develops and commercializes small molecule therapies. The company develops therapies for the treatment of infectious diseases such as chronic hepatitis B virus (HBV) and microbiotic therapies for Clostridium difficile (C. difficile) infections (CDI). It also develops Gemicel platform technology that helps for targeted oral delivery vaccines, live biotherapeutics, small molecules and complex macromolecules which are aimed for specific region in gastrointestinal tract(GI). Assembly’s HBV Cure program target’s the chronic hepatitis B virus infection. The company has research and development facilities in New York, Indiana and California. Assembly is headquartered in Carmel, Indiana, the US.

Assembly Biosciences Inc (ASMB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Assembly Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Ventrus Biosciences Acquires Rights To Iferanserin From Sam Amer For US$23 Million 10
Merger 11
Ventrus Biosciences Completes Merger with Assembly Pharma 11
Licensing Agreements 12
Allergan Enters into Licensing Agreement with Assembly Biosciences 12
Ventrus Biosciences Enters into Licensing Agreement with Therabiome 14
Assembly Biosciences Enters Into Licensing Agreement with Indiana University Research and Technology 15
Assembly Pharma Enters into Licensing Agreement with IURTC 16
Equity Offering 17
Assembly Biosciences Prices Public Offering of Shares for USD60.2 Million 17
Assembly Biosciences Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 18
Assembly Biosciences Raises USD15.8 million in Private Placement of Shares 20
Ventrus Biosciences Announces Public Offering Of Shares For US$20.5 Million 21
Ventrus Biosciences Completes Underwriters’ Exercise Of Over-Allotment Option For Public Offering Of Shares For US$16.7 Million 22
Ventrus Biosciences Completes Public Offering Of Preferred Shares For US$5.5 Million 24
Ventrus Biosciences Completes An Underwritten Public Offering For US$51.8 Million 25
Ventrus Biosciences Completes IPO For US$20 Million 27
Assembly Biosciences Inc – Key Competitors 29
Assembly Biosciences Inc – Key Employees 30
Assembly Biosciences Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Corporate Communications 32
Jul 28, 2017: Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 32
Jan 11, 2016: Assembly Biosciences Expands Senior Leadership Team 33
Product News 35
01/27/2016: Assembly Biosciences Presents Clinical Data at Drug Formulation & Bioavailability Summit Showing Its Oral Gemicel Technology Achieves Targeted Delivery to the Lower GI Tract 35
Clinical Trials 36
Sep 25, 2017: Assembly Biosciences Selects Next-Generation CpAM Candidate for Advancement into Clinical Development 36
Nov 09, 2016: Assembly Biosciences Initiates Phase 1 Clinical Program of ABI-H0731 for Treatment of Chronic Hepatitis B Virus Infection 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Assembly Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Assembly Biosciences Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Ventrus Biosciences Acquires Rights To Iferanserin From Sam Amer For US$23 Million 10
Ventrus Biosciences Completes Merger with Assembly Pharma 11
Allergan Enters into Licensing Agreement with Assembly Biosciences 12
Ventrus Biosciences Enters into Licensing Agreement with Therabiome 14
Assembly Biosciences Enters Into Licensing Agreement with Indiana University Research and Technology 15
Assembly Pharma Enters into Licensing Agreement with IURTC 16
Assembly Biosciences Prices Public Offering of Shares for USD60.2 Million 17
Assembly Biosciences Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 18
Assembly Biosciences Raises USD15.8 million in Private Placement of Shares 20
Ventrus Biosciences Announces Public Offering Of Shares For US$20.5 Million 21
Ventrus Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For US$16.7 Million 22
Ventrus Biosciences Completes Public Offering Of Preferred Shares For US$5.5 Million 24
Ventrus Biosciences Completes An Underwritten Public Offering For US$51.8 Million 25
Ventrus Biosciences Completes IPO For US$20 Million 27
Assembly Biosciences Inc, Key Competitors 29
Assembly Biosciences Inc, Key Employees 30
Assembly Biosciences Inc, Other Locations 31
Assembly Biosciences Inc, Subsidiaries 31

★海外企業調査レポート[Assembly Biosciences Inc (ASMB)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Niska Gas Storage Partners LLC (NKA):企業概要、財務及び戦略的SWOT分析
    Summary Niska Gas Storage Partners LLC (Niska) is a natural gas storage service provider. The company owns and operates natural gas storage assets in North America. It provides multi-year, multi-cycle storage services to its customers under long term firm reserved storage (LTF) contracts. Niska owns …
  • MP2 Capital, LLC:企業のM&A・提携動向(エネルギー分野)
    Summary MP2 Capital, LLC (MP2 Capital) is a renewable energy company that develops, finances and operates solar projects. The company invests in utility scale and distributed generation projects. It finances solar projects for commercial, government, and utility customers under power purchase agreem …
  • Foley Family Wines Limited:企業の戦略・SWOT・財務分析
    SummaryFoley Family Wines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. …
  • Norton Gold Fields Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Norton Gold Fields Limited Merg …
  • Australian Vintage Limited:企業概要・SWOT・財務分析
    Summary Canadean's "Australian Vintage Limited : Consumer Packaged Goods - Company Profile, SWOT and Financial Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, busine …
  • Engineering Ingegneria Informatica SpA (ENG):企業概要、財務及び戦略的SWOT分析
    Summary Engineering Ingegneria Informatica SpA (EII) is an information technology company. The company provides offers business integration, software solutions, application and infrastructure outsourcing, and strategic consultancy services. Its services include application management, augmented real …
  • Kuwait Airways Corporation K.S.C.の企業概要及び財務/SWOT分析
    Kuwait Airways Corporation K.S.C. Fundamental Company Report provides a complete overview of the company’s affairs. The report includes financial and SWOT information, industry analysis, opinions, estimates, Kuwait Airways Corporation K.S.C. annual and quarterly forecasts made by stock market expert …
  • Cancer Genetics, Inc. (CGIX):企業の財務及び戦略的SWOT分析
    Summary Cancer Genetics, Inc. (CGI) is a pharmaceutical company which offers diagnostics products and services in the area of oncology. Its products include DNA-FISH Probes, CGH Microarrays and Next-Generation Sequencing. CGI’s oncology tests and laboratory services provide critical genomic informat …
  • Kian Joo Can Factory Berhad:戦略・SWOT・企業財務分析
    Kian Joo Can Factory Berhad - Strategy, SWOT and Corporate Finance Report Summary Kian Joo Can Factory Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Triumph Group, Inc.:企業のM&A・提携・投資分析
    Triumph Group, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Triumph Group, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Dr. Reddy’s Laboratories Limited:企業の戦略・SWOT・財務分析
    SummaryDr. Reddy's Laboratories Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the com …
  • Dcns S.A.:企業のM&A・提携動向(エネルギー分野)
    Summary Dcns S.A.(Dcns) formerly Direction des Constructions Navales is a naval defense equipment manufacturing company that designs, builds and supports naval defense systems. The company’s products include submarines, warships, surface combatants and associated systems and infrastructures. It offe …
  • Carl Zeiss AG:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Carl Zeiss AG Mergers and Acqui …
  • E.I.D. Parry (India) Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' E.I.D. Parry (India) Limited Me …
  • Perilya Limited:企業の戦略・SWOT・財務分析
    SummaryPerilya Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Finding …
  • Spanco Limited (SPANCO):企業概要、財務及び戦略的SWOT分析
    Summary Spanco Limited (Spanco) is an information technology company. The company operates through its business divisions such as Technology Infrastructure Division and Business Process Outsourcing (BPO) Unit. Its Technology Infrastructure Division offers services in the areas related to eGovernance …
  • Norwegian Air Shuttle AS:企業概要・SWOT・財務分析
    Summary Canadean's "Norwegian Air Shuttle AS : Travel and Tourism - Company Profile, SWOT and Financial Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, business desc …
  • Shinsegae Food Co., Ltd.:企業の戦略・SWOT・財務分析
    SummaryShinsegae Food Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Ke …
  • Dot Foods, Inc.:企業の戦略・SWOT・財務分析
    Dot Foods, Inc. - Strategy, SWOT and Corporate Finance Report Summary Dot Foods, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Softronic AB (SOF B):企業の財務及び戦略的SWOT分析
    Summary Softronic AB (Softronic) is an information technology consulting service provider that develops, delivers and distributes software solutions ,and provides IT and management services. The company’s products include softronic insurance technology management software; appia air sales; appia con …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆